UCB S.A. has kickstarted M&A activity in the pharmaceutical sector for 2022 by expanding its epilepsy business and acquiring Zogenix, Inc. in a deal valued at $1.9bn.
The Belgian group is paying $26.00 per share in cash, which represents a 72% premium to Zogenix's 30-day average closing...








